Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on February 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 451,250 shares of the Company’s common stock and 165,000 restricted stock units to six newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (ZNTL)
- Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
- Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
- Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
- Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
- Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025